论文部分内容阅读
目的 :评价更昔洛韦治疗复发性生殖器疱疹的疗效及安全性。方法 :66例复发性生殖器疱疹患者分两组 ,更昔洛韦组3 6例以间隙疗法静脉滴注更昔洛韦 2 5 0mg ,1次 /日 ,连续 7d ;阿昔洛韦组 3 0例以抑制疗法口服阿昔洛韦 2 0 0mg ,5次 /日 ,连续服 6个月。治疗后随访一年。结果 :更昔洛韦组早期疗效明显好于阿昔洛韦组 ( P <0 0 1) ,而后期疗效两组差异无显著性 ( P >0 0 5 )。两者均无明显毒副作用。结论 :更昔洛韦治疗复发性生殖器疱疹是安全的、速效的
Objective: To evaluate the efficacy and safety of ganciclovir in the treatment of recurrent genital herpes. Methods: Sixty-six patients with recurrent genital herpes were divided into two groups. In the ganciclovir group, ganciclovir was given intravenously at a dose of 250 mg once daily for 7 days, Example to inhibit oral acyclovir 200mg, 5 times / day, continuous service for 6 months. Followed up for one year after treatment. Results: The initial curative effect of ganciclovir group was better than that of acyclovir group (P <0.01), but there was no significant difference between the two groups (P> 0.05). Both have no obvious side effects. Conclusion: Ganciclovir is safe and effective in the treatment of recurrent genital herpes